Sugi Predict

Sugi Predict / Targets / CDKL4

CDKL4

Cyclin-dependent kinase-like 4 · Q5MAI5 · CDKL4 on Sugi Atlas →

718 patent compounds predicted against CDKL4, 703 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL23548732 SCHEMBL23548732 1.00 1/20
SCHEMBL23548122 SCHEMBL23548122 0.88 1/20
SCHEMBL23548619 SCHEMBL23548619 0.85 1/20
SCHEMBL23548280 SCHEMBL23548280 0.84 1/20
SCHEMBL23548092 SCHEMBL23548092 0.83 1/20
SCHEMBL23548369 SCHEMBL23548369 0.83 1/20
SCHEMBL23548383 SCHEMBL23548383 0.83 1/20
SCHEMBL23548626 SCHEMBL23548626 0.83 1/20
SCHEMBL23548806 SCHEMBL23548806 0.82 1/20
SCHEMBL23548228 SCHEMBL23548228 0.81 1/20
SCHEMBL23548573 SCHEMBL23548573 0.81 1/20
SCHEMBL23548607 SCHEMBL23548607 0.81 1/20
SCHEMBL23548689 SCHEMBL23548689 0.81 1/20
SCHEMBL23548903 SCHEMBL23548903 0.81 1/20
SCHEMBL23548366 SCHEMBL23548366 0.80 1/20
SCHEMBL23548302 SCHEMBL23548302 0.80 1/20
SCHEMBL23548459 SCHEMBL23548459 0.80 1/20
SCHEMBL23548560 SCHEMBL23548560 0.80 1/20
SCHEMBL23548691 SCHEMBL23548691 0.80 1/20
SCHEMBL23548473 SCHEMBL23548473 0.79 1/20

Clinical trials — most relevant to CDKL4 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt PHASE4COMPLETED
A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714) PHASE3COMPLETED
Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast Cancer PHASE3ACTIVE_NOT_RECRUITING
A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2) PHASE3COMPLETED
Implementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4/6-inhibitors in Older Breast Cancer Patients PHASE3RECRUITING
Effect of Salovum™ and SPC-Flakes™ on Abemaciclib-induced Gastrointestinal Toxicity in Early Breast Cancer PHASE3UNKNOWN
CDK4/6 Inhibitor Intensification and Chemotherapy De-Escalation for Early-stage Luminal-HER2 Breast Cancer PHASE3NOT_YET_RECRUITING
Determinants of Resistance to Endocrine Therapy and a Cyclin-dependent Kinases 4 and 6 (CDK4/6) Inhibitor for HR+ MBC PHASE2ACTIVE_NOT_RECRUITING
To Reverse ENDocrine Resistance Trial - PD 0332991 Monotherapy vs PD 0332991 in Combination With the Endocrine Therapy PHASE2COMPLETED
Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC) PHASE1/PHASE2RECRUITING
Study of Efficacy of Ribociclib After Progression on CDK4/6 Inhibition in Patients With HR+ HER2- Advanced Breast Cancer PHASE2COMPLETED
Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer PHASE1/PHASE2RECRUITING
CDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast Cancer PHASE2ACTIVE_NOT_RECRUITING
Efficacy Study Of P276-00 In Subjects Of Malignant Melanoma Positive For Cyclin D1 Expression PHASE2COMPLETED
Palbociclib With Everolimus + Exemestane In BC PHASE1/PHASE2COMPLETED
Cyclin Dependent Kinase (CDK)4/6 Inhibitor, PD0332991 in Advanced Non-small Cell Lung Cancer NSCLC. PHASE2COMPLETED
A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer PHASE1/PHASE2RECRUITING
Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer PHASE2RECRUITING
A Study of Palbociclib in Combination With Bazedoxifene in Hormone Receptor Positive Breast Cancer PHASE1/PHASE2COMPLETED
Palbociclib After CDK and Endocrine Therapy (PACE) PHASE2ACTIVE_NOT_RECRUITING
Study of FCN-437c in Patients With Advanced Solid Tumors PHASE1COMPLETED
Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma PHASE1COMPLETED
Clinical Trial of Avasopasem in Patients With Metastatic Hormone Receptor Positive Breast Cancer With Progression on a CDK 4/6 Inhibitor and Hormonal Therapy PHASE1RECRUITING
The SONImage Study nanACTIVE_NOT_RECRUITING
Real-World Clinical Outcomes and Toxicity in Metastatic Breast Cancer Patients Treated With First or Second Line CDK 4/6 Inhibitors and Endocrine Therapy nanCOMPLETED
Advanced Breast Cancer Study of CDK4/6 Inhibitor Combined With Endocrine Therapy Endocrine Therapy in HR+/HER2- Advanced Breast Cancer nanUNKNOWN
Study Of Real-World Evidence In Patients Treated With Palbociclib During a 2.5 Years Follow-Up Period nanUNKNOWN
Utilizing Multiomic Advanced Diagnostics to Identify CDK 4/6 Inhibitor Response Predictors and a Post-treatment Multiomic Signature for Patients With ER+/HER2- Metastatic Breast Cancer nanCOMPLETED
Evaluation of Geriatric Questionnaires to Predict Toxicities of CDK 4/6 Inhibitors in Older Breast Cancer Patients? nanUNKNOWN
Incidence of Venous Thromboembolism and Cardiovascular Events in Breast Cancer Patients Undergoing Cyclin-dependent Kinase 4/6 Inhibitors: The Breast Cancer Associated Vascular Events During Cyclin-dependent Kinase 4/6 Inhibitors Therapy (BRAVE-Cyclin) Study nanACTIVE_NOT_RECRUITING

Related proteins — ESM-2 sequence neighbours (a CDKL4 binder may also engage these)

ProteinNameSimilarity
Q3TZA2 — 1.000 Q3TZA2 →
Q8VZD5 — 1.000 Q8VZD5 →
Q6AXJ9 — 1.000 Q6AXJ9 →
Q8CEQ0 — 1.000 Q8CEQ0 →
P51138 — 0.999 P51138 →
Q66HE7 — 0.998 Q66HE7 →
P43294 — 0.997 P43294 →
P43289 — 0.997 P43289 →
Q9FVS6 — 0.996 Q9FVS6 →
Q40518 — 0.996 Q40518 →
P43288 — 0.996 P43288 →
Q96287 — 0.995 Q96287 →
A8X5H5 — 0.994 A8X5H5 →
P21965 — 0.994 P21965 →
P51137 — 0.994 P51137 →
Q3S406 — 0.994 Q3S406 →
Q755C4 — 0.993 Q755C4 →
CDKL1 Cyclin-dependent kinase-like 1 0.993 landscape →
O23145 — 0.993 O23145 →
Q9U2H1 — 0.993 Q9U2H1 →
Q8MXI4 — 0.993 Q8MXI4 →
Q39011 — 0.993 Q39011 →
O04160 — 0.993 O04160 →
Q5VP69 — 0.993 Q5VP69 →
G4NH08 — 0.992 G4NH08 →
Q39012 — 0.992 Q39012 →
O35832 — 0.992 O35832 →
Q5SN53 — 0.991 Q5SN53 →
Q9U2Q9 — 0.991 Q9U2Q9 →
Q9XTR1 — 0.991 Q9XTR1 →